HIF1A and cancer: Hypoxia has been identified as an inherent impediment to cancer therapy due to its multiple contributions to chemoresistance, angiogenesis, and invasiveness properties.[27] HIF‐1α is the key mediator of the transcriptional responses to hypoxia and plays an important role in cancer proliferation and poor clinical outcomes.[28] The complexes of yes‐associated protein (YAP)/HIF‐1α could accelerate glycolysis under hypoxic conditions by binding to the glycolytic gene promoter.[29] In this study, KEGG pathway analysis showed the enrichment of the HIF‐1 signaling pathway.